Mesoblast Limited (ASX:MSB) Stem Cells Approved For World First Osteoathritis Clinical Trial
Regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that it had received Australian institutional ethics approval to begin the first human trial of adult stem cell treatment for prevention of knee osteoarthritis after an acute traumatic knee injury.
More: continued here
Filed under: Bones on January 24th, 2009
You must be logged in to post a comment.